HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 26,200 shares, an increase of 84.5% from the November 15th total of 14,200 shares. Based on an average daily trading volume, of 21,100 shares, the short-interest ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are sold short.
Wall Street Analyst Weigh In
Separately, Jonestrading began coverage on shares of HCW Biologics in a research note on Monday, November 7th. They issued a "buy" rating and a $8.00 price target on the stock.
Get
HCW Biologics alerts:
Institutional Investors Weigh In On HCW Biologics
Several hedge funds and other institutional investors have recently bought and sold shares of HCWB. HighTower Advisors LLC increased its position in HCW Biologics by 2,056.0% during the first quarter. HighTower Advisors LLC now owns 215,598 shares of the company's stock worth $588,000 after purchasing an additional 205,598 shares during the last quarter. BlackRock Inc. increased its position in HCW Biologics by 136.8% during the first quarter. BlackRock Inc. now owns 39,583 shares of the company's stock worth $108,000 after purchasing an additional 22,869 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in HCW Biologics by 9.8% during the third quarter. Vanguard Group Inc. now owns 95,392 shares of the company's stock worth $218,000 after purchasing an additional 8,494 shares during the last quarter. 1.59% of the stock is currently owned by institutional investors and hedge funds.
HCW Biologics Price Performance
HCW Biologics stock traded up $0.17 during midday trading on Thursday, hitting $2.10. 67,140 shares of the stock were exchanged, compared to its average volume of 33,825. HCW Biologics has a fifty-two week low of $1.76 and a fifty-two week high of $3.32. The stock's 50-day simple moving average is $2.18 and its 200 day simple moving average is $2.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 12.52 and a quick ratio of 12.52.
HCW Biologics Company Profile
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
See Also
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
